KRN 330

Drug Profile

KRN 330

Alternative Names: KRN-330

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kirin Pharma Company
  • Developer Kyowa Hakko Kirin
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Differentiation antigen inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Colorectal cancer

Most Recent Events

  • 18 Oct 2012 Discontinued - Phase-I for Colorectal cancer in USA (Parenteral)
  • 18 Oct 2012 Discontinued - Phase-I/II for Colorectal cancer (combination therapy) in USA (Parenteral)
  • 10 Oct 2012 Kyoa Hakko Kirin terminates a phase I/IIa trial in Colorectal cancer in US (NCT00838578)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top